Revelation Biosciences, Inc.
REVB
$0.93
-$0.02-2.04%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -10.76% | -7.52% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -21.05% | 17.48% | |||
| Operating Income | 21.05% | -17.48% | |||
| Income Before Tax | 21.98% | -19.18% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 21.98% | -19.18% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 21.98% | -19.18% | |||
| EBIT | 21.05% | -17.48% | |||
| EBITDA | 21.10% | -17.54% | |||
| EPS Basic | 74.77% | -10.64% | |||
| Normalized Basic EPS | 76.32% | 51.93% | |||
| EPS Diluted | 74.77% | -10.64% | |||
| Normalized Diluted EPS | 76.32% | 51.93% | |||
| Average Basic Shares Outstanding | 229.48% | 147.90% | |||
| Average Diluted Shares Outstanding | 229.48% | 147.90% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||